In conclusion, although our study deserves further confirmation by in vivo studies and by clinical trials, we demonstrated the possible mechanism by which the pharmacological targeting of TRPV2 with tranilast can be useful to overcome drug resistance, a major limitation of current therapeutic regimens for GC. This evidence concerns the gene TRPV2 and gastric cancer.